Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01YVZ
|
|||
| Former ID |
DNCL003095
|
|||
| Drug Name |
GLYX-13
|
|||
| Synonyms |
Rapastinel; 117928-94-6; GLYX-13; GLYX 13; GLYX13; UNII-6A1X56B95E; L-Threoninamide, L-threonyl-L-prolyl-L-prolyl-; 6A1X56B95E; (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide; GLYX-13 trifluoroacetate; TPPT-amide trifluoroacetate; TPPT-amide; GLYX-13 peptide; Rapastinel [USAN:INN]; GLYX13;Rapastinel; Rapastinel(GLYX-13); L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate; Thr-Pro-Pro-Thr-NH2 trifluoroacetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 3 | [1] | |
| Company |
Naurex
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H31N5O6
|
|||
| Canonical SMILES |
CC(C(C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)N)N)O
|
|||
| InChI |
1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1
|
|||
| InChIKey |
GIBQQARAXHVEGD-BSOLPCOYSA-N
|
|||
| CAS Number |
CAS 117928-94-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Agonist | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.